ANI Pharmaceuticals Raises FY23 Adjusted non-GAAP EPS Guidance To $3.62-$4.11 From $2.99-$3.45, Vs. Consensus Of $3.31
Portfolio Pulse from Benzinga Newsdesk
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has raised its FY23 adjusted non-GAAP EPS guidance to $3.62-$4.11 from $2.99-$3.45, beating the consensus of $3.31. The revised guidance represents YoY growth in net revenues of 37%, adjusted non-GAAP EBITDA of 115%, and adjusted non-GAAP earnings per diluted share of 184%.
August 09, 2023 | 10:58 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ANI Pharmaceuticals has raised its FY23 EPS guidance, indicating strong future performance. This could lead to a positive impact on the company's stock price.
ANI Pharmaceuticals has raised its FY23 EPS guidance significantly above the consensus, indicating strong future performance. This is likely to be viewed positively by investors, potentially leading to an increase in the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100